Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | First-in-human study of autologous memory-like NK cells in patients with MRD+ multiple myeloma

Giada Bianchi • 29 Sep 2023
IMS 2023
Multiple Myeloma BHV-1100 NK-Cell Therapy

Giada Bianchi, MD, Brigham and Women’s Hospital & Dana-Farber Cancer Institute, Boston, MA, shares findings from a first-in-human trial exploring the safety and efficacy of autologous memory-like NK cells in patients with multiple myeloma undergoing autologous stem cell transplantation (autoSCT). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Giada Bianchi

1:53
Novel laboratory-based therapeutic approach in AL amyloidosis: investigating FLC secretion
Giada Bianchi • 29 Sep 2023
1:48
Investigating the proteasome stress response as a potential novel therapeutic target in myeloma
Giada Bianchi • 29 Sep 2023
1:52
The impact of CHIP in patients with AL amyloidosis
Giada Bianchi • 29 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals